florgane 300 mg/ml injektionsvæske, suspension
emdoka - florfenicol - injektionsvæske, suspension - 300 mg/ml - kvæg, svin
kelaflor 300 mg/ml injektionsvæske, opløsning
kela laboratoria n.v. - florfenicol - injektionsvæske, opløsning - 300 mg/ml - kvæg, svin
norfenicol 300 mg/ml injektionsvæske, opløsning
norbrook laboratories (ireland) limited - florfenicol - injektionsvæske, opløsning - 300 mg/ml - kvæg, svin
nuflor minidose 450 mg/ml injektionsvæske, opløsning
intervet international b.v. - florfenicol - injektionsvæske, opløsning - 450 mg/ml - kvæg
shotaflor 300 mg/ml injektionsvæske, opløsning
virbac s.a. - florfenicol - injektionsvæske, opløsning - 300 mg/ml - svin
tilmicosol 250 mg/ml koncentrat til oral opløsning til brug i drikkevand
lavet pharmaceuticals ltd. - tilmicosinphosphat - koncentrat til oral opløsning til brug i drikkevand - 250 mg/ml - fjerkræ, kvæg, svin
veraseal
instituto grifols, s.a. - humant fibrinogen, human thrombin - hemostase, kirurgisk - antihemorrhagics - understøttende behandling hos voksne, hvor standard kirurgiske teknikker er utilstrækkelige:for forbedring af haemostasisas sutur støtte i karkirurgi.
tildosin 250 mg/ml opløsning til anvendelse i drikkevand/mælk
dopharma research b.v. - tilmicosin - opløsning til anvendelse i drikkevand/mælk - 250 mg/ml - fjerkræ, kvæg, svin
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
doxycyclin "paranova" 100 mg tabletter
paranova danmark a/s - doxycyclinmonohydrat - tabletter - 100 mg